Sexual health-related psychological and emotional life after allogeneic haematopoietic stem-cell transplantation
- PMID: 39312922
- DOI: 10.1016/S2352-3026(24)00209-6
Sexual health-related psychological and emotional life after allogeneic haematopoietic stem-cell transplantation
Abstract
Sexual health is important for the quality of life of patients who have received haematopoietic stem-cell transplantation (HSCT). Sexual dysfunction and couple dissatisfaction can seriously affect a patient's recovery and treatment process. However, this aspect of post-transplantation recovery is still usually neglected in clinical practice. In this Series paper, we aim to elucidate the emotional and psychosocial factors affecting the sexual function in these patients, with a special focus on the partner's role and the psychological consequences of some adverse effects of HSCT. Moreover, we provide an overview of the management approaches and assessment tools of psychological issues associated with sexual dysfunction reported in the literature. These tools can help clinicians in this field to plan essential lifestyle and clinical interventions to help their patients. In conclusion, screening for psychological issues is indispensable when approaching sexual dysfunction in patients with HSCT. Health-care teams in transplantation units should be trained to discuss this aspect of recovery and provide the required treatment and follow-up plan.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests LA declares a PhD scholarship by PAUSE (Programme d'aide à l'Accueil en Urgence des Scientifiques en Exil). YC has received honoraria from Abbvie, Amgen, Astra-Zeneca, Bristol Myers Squibb, Gilead, Incyte, Jazz, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Servier, and Takeda; and travel support from Abbvie, Amgen, Astra-Zeneca, Bristol Myers Squibb, Gilead, Incyte, Jazz, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Sanofi. AL is an unpaid member of the European Society for Blood and Marrow Transplantation (EBMT) Patient Advocacy Committee (board member). HS declares grants or contracts, paid to her institution, from Novartis and the Belgian Hematological Society; consulting fees, paid to her institution, from Incyte, Janssen, Novartis, and Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events, paid to her institution, from Novartis and the Belgian Hematological Society; support for attending meetings and travel, paid to her institution, from Pfizer, Gilead, EBMT, and Center for International Bone Marrow Transplantation Research; participation on a Data Safety Monitoring Board or Advisory Board for Hôpital Saint-Louis, Paris, France (unpaid); and leadership or fiduciary roles for EBMT (unpaid), the Center for International Bone Marrow Transplantation Research (unpaid voluntary work), and Belgian Hematological Society (unpaid). TA declares consulting fees from Biotest and Amgen; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from biotest; receiving meeting or travel support from Biotest, Sandoz, Novartis, Astellas Pharma, and Viatris; and leadership or fiduciary roles for the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (unpaid, responsible for practice harmonisation group). MM declares grants or contracts (outside of the present Series papers) from Sanofi, Novartis, and Janssen; consulting fees from Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, and Takeda; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Adaptive Biotechnologies, Amgen, Astellas, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Jazz, Novartis, Pfizer, Sanofi, Stemline, Takeda, and MaaT; participation on a Data Safety Monitoring Board or Advisory Board for Janssen; and leadership or fiduciary role for EBMT and the International Academy for Clinical Hematology. FM declares payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Therakos–Mallinckrodt, Sanofi, Bristol Myers Squibb, Merck Sharp & Dohme, Astrazeneca, Jazz Pharmaceuticals, Gilead, and Novartis. ZP declares consulting fees from Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Therakos, Sanofi, Pfizer, and Astrazeneca; and was the transplant complications working party chair for EBMT. All other authors declare no competing interests.
Similar articles
-
Sexual health in hematopoietic stem cell transplant recipients.Cancer. 2015 Dec 1;121(23):4124-31. doi: 10.1002/cncr.29675. Epub 2015 Sep 15. Cancer. 2015. PMID: 26372459 Free PMC article. Review.
-
A comprehensive review of sexual health concerns after cancer treatment and the biopsychosocial treatment options available to female patients.Eur J Cancer Care (Engl). 2018 Mar;27(2):e12738. doi: 10.1111/ecc.12738. Epub 2017 Aug 10. Eur J Cancer Care (Engl). 2018. PMID: 28795458 Review.
-
Sexuality after hematopoietic stem cell transplantation.Cancer J. 2009 Jan-Feb;15(1):57-64. doi: 10.1097/PPO.0b013e318198c758. Cancer J. 2009. PMID: 19197175 Free PMC article.
-
Sexual dysfunction after hematopoietic stem cell transplantation.Oncol Nurs Forum. 2011 Jul;38(4):409-12. doi: 10.1188/11.ONF.409-412. Oncol Nurs Forum. 2011. PMID: 21708531 No abstract available.
-
Management of sexual problems in cancer patients and survivors.Curr Probl Cancer. 2013 Nov-Dec;37(6):319-52. doi: 10.1016/j.currproblcancer.2013.10.009. Epub 2013 Oct 22. Curr Probl Cancer. 2013. PMID: 24331239 Review. No abstract available.
Cited by
-
Genital Graft-Versus-Host-Disease Predicts Decreased Sexual Function in Female Survivors of Allogeneic Hematopoietic Stem Cell Transplant.Transplant Cell Ther. 2025 Jun 18:S2666-6367(25)01262-X. doi: 10.1016/j.jtct.2025.06.021. Online ahead of print. Transplant Cell Ther. 2025. PMID: 40541681
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical